Previous 10 | Next 10 |
home / stock / bpmuf / bpmuf news
Allschwil, Switzerland, May 03, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that scientific presentations with new data on its anti...
Allschwil, Switzerland, April 09, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has been awarded a grant from CARB-X (Combati...
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, April 04, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today th...
Allschwil, Switzerland, March 11, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the an...
2024-02-13 09:18:40 ET More on Basilea Pharmaceutica AG Historical earnings data for Basilea Pharmaceutica AG Financial information for Basilea Pharmaceutica AG Read the full article on Seeking Alpha For further details see: Basilea Pharmaceutica AG GAAP ...
ESSA Pharma Inc. (EPIX) is expected to report $-0.17 for Q1 2024 QuidelOrtho Corp Com (QDEL) is expected to report $2.01 for Q4 2023 FaZe Holdings Inc. (FAZE) is expected to report for Q4 2023 Portsmouth Square, Inc. (PRSI) is expected to report for Q2 2024 Similarweb Ltd. (SMWB) ...
Basilea Pharmaceutica AG Registered Shares (BPMUF) is expected to report for Q4 2023
Increased Cresemba ® and Zevtera ® -related revenue of CHF 150.3 million (+22.9% year-on-year) at upper end of guidance Operating profit of CHF 19.2 million and net profit of CHF 10.5 million, significantly above guidance Addition of three new ant...
Allschwil, Switzerland, January 19, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the sales of the antifungal Cresemba ® ...
Novel class of antibiotics Bactericidal activity demonstrated in vitro and in vivo against broad range of Gram-negative bacteria, including multidrug-resistant strains Allschwil, Switzerland, January 15, 2024 Basilea Pharmaceutica Ltd, Allschwil (SI...
News, Short Squeeze, Breakout and More Instantly...
Basilea Pharm Ag Akt Shs Company Name:
BPMUF Stock Symbol:
OTCMKTS Market:
China Yuchai International Limited (CYD) is expected to report for Q1 2024 Avid Bioservices Inc. (CDMO) is expected to report $0.03 for Q4 2024 Derwent London Plc (DWVYF) is expected to report for Q1 2024 Fresnillo Plc (FNLPF) is expected to report for Q1 2024 Basilea Pharmaceutic...
GreenTree Hospitality Group Ltd. American depositary shares each representing one Class A (GHG) is expected to report for Q1 2024 Air T Inc. (AIRT) is expected to report for Q4 2024 Alimentation-Couche Tard Inc. - Class A (Multiple Voting) (ANCTF) is expected to report for Q4 2024 Man...
Allschwil, Switzerland, June 20, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has entered into an asset purchase agreement w...